Sphera Funds Management LTD. decreased its position in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) by 24.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 490,000 shares of the biotechnology company’s stock after selling 156,273 shares during the period. Sphera Funds Management LTD. owned 1.72% of Genocea Biosciences worth $2,558,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in GNCA. FMR LLC increased its position in Genocea Biosciences by 0.4% in the first quarter. FMR LLC now owns 4,274,804 shares of the biotechnology company’s stock worth $26,033,000 after buying an additional 18,574 shares in the last quarter. Northpointe Capital LLC increased its position in Genocea Biosciences by 9.6% in the second quarter. Northpointe Capital LLC now owns 1,336,062 shares of the biotechnology company’s stock worth $6,974,000 after buying an additional 117,374 shares in the last quarter. Geode Capital Management LLC increased its position in Genocea Biosciences by 4.7% in the first quarter. Geode Capital Management LLC now owns 148,370 shares of the biotechnology company’s stock worth $903,000 after buying an additional 6,708 shares in the last quarter. Bank of New York Mellon Corp increased its position in Genocea Biosciences by 594.6% in the second quarter. Bank of New York Mellon Corp now owns 84,119 shares of the biotechnology company’s stock worth $439,000 after buying an additional 72,008 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. acquired a new position in Genocea Biosciences during the second quarter worth about $257,000. Hedge funds and other institutional investors own 59.25% of the company’s stock.

Genocea Biosciences, Inc. (NASDAQ GNCA) opened at 4.96 on Friday. Genocea Biosciences, Inc. has a 12-month low of $3.28 and a 12-month high of $7.29. The stock’s market cap is $141.98 million. The firm has a 50 day moving average of $4.83 and a 200-day moving average of $5.49.

Genocea Biosciences (NASDAQ:GNCA) last issued its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.08. On average, analysts expect that Genocea Biosciences, Inc. will post ($1.98) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Sphera Funds Management LTD. Sells 156,273 Shares of Genocea Biosciences, Inc. (GNCA)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/09/03/sphera-funds-management-ltd-sells-156273-shares-of-genocea-biosciences-inc-gnca.html.

GNCA has been the subject of several recent analyst reports. Needham & Company LLC upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Monday, July 24th. Zacks Investment Research downgraded shares of Genocea Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Cowen and Company restated an “outperform” rating and issued a $40.00 target price on shares of Genocea Biosciences in a research note on Tuesday, July 25th. ValuEngine downgraded shares of Genocea Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $18.00 target price (up from $17.00) on shares of Genocea Biosciences in a research note on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. Genocea Biosciences presently has an average rating of “Buy” and an average target price of $16.52.

In other news, CFO Jonathan Poole sold 45,000 shares of the company’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $6.00, for a total value of $270,000.00. Following the completion of the transaction, the chief financial officer now owns 84,247 shares in the company, valued at approximately $505,482. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 6.70% of the company’s stock.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Institutional Ownership by Quarter for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Stock Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related stocks with our FREE daily email newsletter.